jCyte Identifies Key Anatomical Biomarker Predictive of Substantial Restoration of Visual Function in Retinitis Pigmentosa Patients Treated With jCell Therapy
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--jCyte, Inc., today announced key findings presented at AAO 2021 which demonstrated that retinitis pigmentosa (RP) patients with a baseline central visual field diameter greater than 20 degrees had a profound response to jCell treatment in its Phase 2b study, the largest randomized clinical trial ever conducted in RP for a locally administered investigational treatment. Baruch Kuppermann, MD, PhD, Chairman of the Department of Ophthalmology at the UCI Gavi